Cargando…

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype

SIMPLE SUMMARY: Molecular analyses discussed in Molecular Tumor Boards are expected to improve cancer treatment by identifying tumor-specific alterations. Here, we quantified the expression of the gangliosides GD2 and N-glycolyl GM3 in neuroblastoma and medulloblastoma, two aggressive pediatric tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Paret, Claudia, Ustjanzew, Arsenij, Ersali, Sara, Seidmann, Larissa, Jennemann, Richard, Ziegler, Nicole, Malki, Khalifa El, Russo, Alexandra, Wingerter, Arthur, Ortmüller, Franziska, Bornas, Angelina, Wehling, Pia Charlotte, Lepădatu, Adina, Ottenhausen, Malte, Roth, Wilfried, Sommer, Clemens, Fliss, Barbara, Frauenknecht, Katrin B. M., Sandhoff, Roger, Faber, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775636/
https://www.ncbi.nlm.nih.gov/pubmed/36551537
http://dx.doi.org/10.3390/cancers14246051
_version_ 1784855693353811968
author Paret, Claudia
Ustjanzew, Arsenij
Ersali, Sara
Seidmann, Larissa
Jennemann, Richard
Ziegler, Nicole
Malki, Khalifa El
Russo, Alexandra
Wingerter, Arthur
Ortmüller, Franziska
Bornas, Angelina
Wehling, Pia Charlotte
Lepădatu, Adina
Ottenhausen, Malte
Roth, Wilfried
Sommer, Clemens
Fliss, Barbara
Frauenknecht, Katrin B. M.
Sandhoff, Roger
Faber, Jörg
author_facet Paret, Claudia
Ustjanzew, Arsenij
Ersali, Sara
Seidmann, Larissa
Jennemann, Richard
Ziegler, Nicole
Malki, Khalifa El
Russo, Alexandra
Wingerter, Arthur
Ortmüller, Franziska
Bornas, Angelina
Wehling, Pia Charlotte
Lepădatu, Adina
Ottenhausen, Malte
Roth, Wilfried
Sommer, Clemens
Fliss, Barbara
Frauenknecht, Katrin B. M.
Sandhoff, Roger
Faber, Jörg
author_sort Paret, Claudia
collection PubMed
description SIMPLE SUMMARY: Molecular analyses discussed in Molecular Tumor Boards are expected to improve cancer treatment by identifying tumor-specific alterations. Here, we quantified the expression of the gangliosides GD2 and N-glycolyl GM3 in neuroblastoma and medulloblastoma, two aggressive pediatric tumors. Our data suggest that subtypes of both entities will benefit from an anti-GD2 directed therapy, and that the ganglioside signature can be helpful in the identification of GD2-positive samples. The integration of lipid analysis may help to identify patients who will benefit from personalized immunotherapy with monoclonal antibodies or CAR-T cells. ABSTRACT: Neuroblastoma (NBL) and medulloblastoma (MB) are aggressive pediatric cancers which can benefit from therapies targeting gangliosides. Therefore, we compared the ganglioside profile of 9 MB and 14 NBL samples by thin layer chromatography and mass spectrometry. NBL had the highest expression of GD2 (median 0.54 nmol GD2/mg protein), and also expressed complex gangliosides. GD2-low samples expressed GD1a and were more differentiated. MB mainly expressed GD2 (median 0.032 nmol GD2/mg protein) or GM3. Four sonic hedgehog-activated (SHH) as well as one group 4 and one group 3 MBs were GD2-positive. Two group 3 MB samples were GD2-negative but GM3-positive. N-glycolyl neuraminic acid-containing GM3 was neither detected in NBL nor MB by mass spectrometry. Furthermore, a GD2-phenotype predicting two-gene signature (ST8SIA1 and B4GALNT1) was applied to RNA-Seq datasets, including 86 MBs and validated by qRT-PCR. The signature values were decreased in group 3 and wingless-activated (WNT) compared to SHH and group 4 MBs. These results suggest that while NBL is GD2-positive, only some MB patients can benefit from a GD2-directed therapy. The expression of genes involved in the ganglioside synthesis may allow the identification of GD2-positive MBs. Finally, the ganglioside profile may reflect the differentiation status in NBL and could help to define MB subtypes.
format Online
Article
Text
id pubmed-9775636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97756362022-12-23 GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype Paret, Claudia Ustjanzew, Arsenij Ersali, Sara Seidmann, Larissa Jennemann, Richard Ziegler, Nicole Malki, Khalifa El Russo, Alexandra Wingerter, Arthur Ortmüller, Franziska Bornas, Angelina Wehling, Pia Charlotte Lepădatu, Adina Ottenhausen, Malte Roth, Wilfried Sommer, Clemens Fliss, Barbara Frauenknecht, Katrin B. M. Sandhoff, Roger Faber, Jörg Cancers (Basel) Article SIMPLE SUMMARY: Molecular analyses discussed in Molecular Tumor Boards are expected to improve cancer treatment by identifying tumor-specific alterations. Here, we quantified the expression of the gangliosides GD2 and N-glycolyl GM3 in neuroblastoma and medulloblastoma, two aggressive pediatric tumors. Our data suggest that subtypes of both entities will benefit from an anti-GD2 directed therapy, and that the ganglioside signature can be helpful in the identification of GD2-positive samples. The integration of lipid analysis may help to identify patients who will benefit from personalized immunotherapy with monoclonal antibodies or CAR-T cells. ABSTRACT: Neuroblastoma (NBL) and medulloblastoma (MB) are aggressive pediatric cancers which can benefit from therapies targeting gangliosides. Therefore, we compared the ganglioside profile of 9 MB and 14 NBL samples by thin layer chromatography and mass spectrometry. NBL had the highest expression of GD2 (median 0.54 nmol GD2/mg protein), and also expressed complex gangliosides. GD2-low samples expressed GD1a and were more differentiated. MB mainly expressed GD2 (median 0.032 nmol GD2/mg protein) or GM3. Four sonic hedgehog-activated (SHH) as well as one group 4 and one group 3 MBs were GD2-positive. Two group 3 MB samples were GD2-negative but GM3-positive. N-glycolyl neuraminic acid-containing GM3 was neither detected in NBL nor MB by mass spectrometry. Furthermore, a GD2-phenotype predicting two-gene signature (ST8SIA1 and B4GALNT1) was applied to RNA-Seq datasets, including 86 MBs and validated by qRT-PCR. The signature values were decreased in group 3 and wingless-activated (WNT) compared to SHH and group 4 MBs. These results suggest that while NBL is GD2-positive, only some MB patients can benefit from a GD2-directed therapy. The expression of genes involved in the ganglioside synthesis may allow the identification of GD2-positive MBs. Finally, the ganglioside profile may reflect the differentiation status in NBL and could help to define MB subtypes. MDPI 2022-12-08 /pmc/articles/PMC9775636/ /pubmed/36551537 http://dx.doi.org/10.3390/cancers14246051 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Paret, Claudia
Ustjanzew, Arsenij
Ersali, Sara
Seidmann, Larissa
Jennemann, Richard
Ziegler, Nicole
Malki, Khalifa El
Russo, Alexandra
Wingerter, Arthur
Ortmüller, Franziska
Bornas, Angelina
Wehling, Pia Charlotte
Lepădatu, Adina
Ottenhausen, Malte
Roth, Wilfried
Sommer, Clemens
Fliss, Barbara
Frauenknecht, Katrin B. M.
Sandhoff, Roger
Faber, Jörg
GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
title GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
title_full GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
title_fullStr GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
title_full_unstemmed GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
title_short GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
title_sort gd2 expression in medulloblastoma and neuroblastoma for personalized immunotherapy: a matter of subtype
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775636/
https://www.ncbi.nlm.nih.gov/pubmed/36551537
http://dx.doi.org/10.3390/cancers14246051
work_keys_str_mv AT paretclaudia gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT ustjanzewarsenij gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT ersalisara gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT seidmannlarissa gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT jennemannrichard gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT zieglernicole gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT malkikhalifael gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT russoalexandra gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT wingerterarthur gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT ortmullerfranziska gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT bornasangelina gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT wehlingpiacharlotte gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT lepadatuadina gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT ottenhausenmalte gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT rothwilfried gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT sommerclemens gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT flissbarbara gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT frauenknechtkatrinbm gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT sandhoffroger gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype
AT faberjorg gd2expressioninmedulloblastomaandneuroblastomaforpersonalizedimmunotherapyamatterofsubtype